Contribution of non primate animal models in understanding the etiology of schizophrenia

Journal of Psychiatry and Neuroscience

Volumn 36, Issue 4, 2011, Pages E5-E29

  Lazar, Noah L ^a   Neufeld, Richard W J ^a   Cain, Donald P ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; DEXTRO AMINO ACID OXIDASE; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; DYSBINDIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; NEU DIFFERENTIATION FACTOR; PROLINE DEHYDROGENASE; PROTEIN ZDHHC8; RECEPTOR PROTEIN; RETICULON 4; RETICULON 4 RECEPTOR; RGS4 PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ANIMAL DISEASE; BRAIN DEVELOPMENT; COGNITIVE DEFECT; DISEASE MODEL; ENVIRONMENTAL FACTOR; GENETIC RISK; HUMAN; MEDICAL RESEARCH; NEGATIVE SYNDROME; NEUROANATOMY; NEUROTRANSMITTER RELEASE; NONHUMAN; PHENOTYPE; POSITIVE SYNDROME; PRIMATE; REVIEW; RODENT; SCHIZOPHRENIA; ANIMAL; RISK FACTOR;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; RISK FACTORS; SCHIZOPHRENIA;

EID: 79959668200     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.100054     Document Type: Review

References (336)

1. Mao CV, Hori E, Maior RS, et al. A primate model of schizophrenia using chronic PCP treatment. Rev Neurosci 2008;19:83-9.
2. Miczek KA, Yoshimura H. Disruption of primate social behavior by d-amphetamine and cocaine: differential antagonism by anti -psychotics. Psychopharmacology (Berl) 1982;76:163-71.
3. Nicholson IR, Chapman JE, Neufeld RW. Variability in BPRS definitions of positive and negative symptoms. Schizophr Res 1995;17:177-85.
4. Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull 2007;33:1013-22.
5. Tamminga CA, Holcomb HH. Phenotype of schizophrenia: a review and formulation. Mol Psychiatry 2005;10:27-39.
6. Heinrichs RW. The primacy of cognition in schizophrenia. Am Psychol 2005;60:229-42.
7. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizo phrenia: speculations on pathogenesis, pathophysiology, and rapeuticpproaches. Biol Psychiatry 2001;50:884-97.
8. Marenco S, Weinberger DR. The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev Psychopathol 2000;12:501-27.
9. Abi-Dargham A, Gil R, Krystal J, et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998;155:761-7.
10. Kessler RM, Woodward ND, Riccardi P, et al. Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry 2009;65:1024-31.
11. Lyon GJ, Abi-Dargham A, Moore H et al. Presynaptic regulation of dopamine transmission in schizophrenia. Schizophr Bull 2009 Jun. 12. [Epub ahead of print]
12. Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 2005;20:15-27.
13. Ananth J, Burgoyne KS, Gadasalli R, et al. How do the atypical antipsychotics work? J Psychiatry Neurosci 2001;26:385-94.
14. Faustman WO, Bardgett M, Faull KF, et al. Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients. Biol Psychiatry 1999;45:68-75.
15. Moghaddam B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 2004;174:39-44.
16. Tsai G, Passani LA, Slusher BS, et al. Abnormal excitatory neuro-transmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 1995;52:829-36.
17. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-8.
18. Akbarian S, Kim JJ, Potkin SG, et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995;52:258-66.
19. Volk D, Austin M, Pierri J, et al. GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. Am J Psychiatry 2001;158:256-65.
20. Benes FM, Khan Y, Vincent SL, et al. Differences in the sub regional and cellular distribution of GABAA receptor binding in the hip-pocampal formation of schizophrenic brain. Synapse 1996;22:338-49.
21. Andreasen NC, Ehrhardt JC, Swayze VW, et al. Magnetic resonance imaging of the brain in schizophrenia. The pathophysiologic significance of structural abnormalities. Arch Gen Psychiatry 1990; 47: 35-44.
22. Kelsoe JR Jr, Cadet JL, Pickar D, et al. Quantitative neuroanatomy in schizophrenia. A controlled magnetic resonance imaging study. Arch Gen Psychiatry 1988;45:533-41.
23. Schlaepfer TE, Harris GJ, Tien AY, et al. Decreased regional cortical gray matter volume in schizophrenia. Am J Psychiatry 1994;151:842-8.
24. Buchanan RW, Vladar K, Barta PE, et al. Structural evaluation of the prefrontal cortex in schizophrenia. Am J Psychiatry 1998;155:1049-55.
25. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry 1999;45:17-25.
26. Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999;122(Pt 4):593-624.
27. Jakob H, Beckmann H. Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J Neural Transm 1986;65:303-26.
28. Okugawa G, Sedvall GC, Agartz I. Reduced grey and white matter volumes in the temporal lobe of male patients with chronic schizophrenia. Eur Arch Psychiatry Clin Neurosci 2002;252:120-3.
29. Sanfilipo M, Lafargue T, Rusinek H, et al. Volumetric measure of the frontal and temporal lobe regions in schizophrenia: relationship to negative symptoms. Arch Gen Psychiatry 2000;57:471-80.
30. Anderson JE, Wible CG, McCarley RW, et al. An MRI study of temporal lobe abnormalities and negative symptoms in chronic schizophrenia. Schizophr Res 2002;58:123-34.
31. Heckers S, Konradi C. Hippocampal neurons in schizophrenia. J Neural Transm 2002;109:891-905.
32. Arnold SE. The medial temporal lobe in schizophrenia. J Neuropsychiatry Clin Neurosci 1997;9:460-70.
33. Bogerts B, Lieberman JA, Ashtari M, et al. Hippocampus-amygdala volumes and psychopathology in chronic schizophrenia. Biol Psychiatry 1993;33:236-46.
34. Rajarethinam R, DeQuardo JR, Miedler J, et al. Hippocampus and amygdala in schizophrenia: assessment of the relationship of neuroanatomy to psychopathology. Psychiatry Res 2001;108:79-87.
35. Vita A, De PL, Silenzi C, et al. Brain morphology in first-episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. Schizophr Res 2006;82:75-88.
36. Harrison PJ. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology (Berl) 2004;174:151-62.
37. Zaidel DW. Regional differentiation of neuron morphology in human left and right hippocampus: comparing normal to schizophrenia. Int J Psychophysiol 1999;34:187-96.
38. Csernansky JG, Schindler MK, Splinter NR, et al. Abnormalities of thalamic volume and shape in schizophrenia. Am J Psychiatry 2004; 161:896-902.
39. Keshavan MS, Rosenberg D, Sweeney JA, et al. Decreased caudate volume in neuroleptic-naive psychotic patients. Am J Psychiatry 1998; 155:774-8.
40. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-9.
41. Cannon TD, Kaprio J, Lonnqvist J, et al. The genetic epidemiology of schizophrenia in a Finnish twin cohort. A population-based modeling study. Arch Gen Psychiatry 1998;55:67-74.
42. Murray RM, Castle DJ. Genetic and environmenal risk factors for schizophrenia. In: Gelder MG, Lopez-Ibor JJ Jr, Andreasen NC, editors. New Oxford textbook of psychiatry. Vol. 1. Toronto (ON): Oxford University Press; 2000. p. 599-605.
43. Pogue-Geile MF, Gottesman II. Schizophrenia: study of a gen -etically complex phenotype. In: Jones BC, Mormede P, editors. Neuro behavioral genetics: methods and applications. New York (NY): CRC Press; 1999. p. 247-64.
44. Karkowski L. Human family studies. In: Jones BC, Mormede P, editors. Neurobehavioral genetics: methods and applications. New York (NY): CRC Press; 1999. p. 151-62.
45. Carlier M, Spitz E. The twin method. In: Jones BC, Mormede P, editors. Neurobehavioral genetics: methods and applications. New York (NY): CRC Press; 1999. p. 141-50.
46. Gottesman II, Bertelsen A. Confirming unexpressed genotypes for schizophrenia. Risks in the offspring of Fischer's Danish identical and fraternal discordant twins. Arch Gen Psychiatry 1989;46:867-72.
47. Heston LL. Psychiatric disorders in foster home reared children of schizophrenic mothers. Br J Psychiatry 1966;112:819-25.
48. Kety SS. Schizophrenic illness in the families of schizophrenic adoptees: findings from the Danish national sample. Schizophr Bull 1988;14:217-22.
49. Owen MJ, O'Donovan MC. Schizophrenia genetics. In: Plomin R, Defries JC, Craig IW, et al., editors. Behavioral genetics in the post -genomic era. Washington (DC): American Psychological Association; 2003. p. 463-82.
50. Moises H, Zoega T, Li L, et al. Genes and neurodevelopment in schizophrenia. In: DiLalla LF, editor. Behavior genetics principles: perspectives in development, personality, and psychopathology. Washington (DC): American Psychological Association; 2004. p. 145-57.
51. Neves-Pereira M, Cheung JK, Pasdar A, et al. BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry 2005; 10:208-12.
52. Nicholson IR, Neufeld RW. Classification of the schizophrenias according to symptomatology: a two-factor model. J Abnorm Psychol 1993;102:259-70.
53. Beauchaine TP. The role of biomarkers and endophenotypes in prevention and treatment of psychopathological disorders. Biomark Med 2009;3:1-3.
54. Gottesman II, Gould TD. The endophenotype concept in psych -iatry: etymology and strategic intentions. Am J Psychiatry 2003;160: 636-45.
55. Braff DL, Freedman R, Schork NJ, et al. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr Bull 2007;33:21-32.
56. Cannon TD. The inheritance of intermediate phenotypes for schizo phrenia. Curr Opin Psychiatry 2005;18:135-40.
57. Matthysse S, Holzman PS, Gusella JF, et al. Linkage of eye movement dysfunction to chromosome 6p in schizophrenia: additional evidence. Am J Med Genet B Neuropsychiatr Genet 2004;128B:30-6.
58. Bearden CE, Freimer NB. Endophenotypes for psychiatric disorders: Ready for primetime? Trends Genet 2006;22:306-13.
59. Hong LE, Mitchell BD, Avila MT, et al. Familial aggregation of eye-tracking endophenotypes in families of schizophrenic patients. Arch Gen Psychiatry 2006;63:259-64.
60. Neufeld RWJ, Williamson P. Neuropsychological correlates of positive symptoms: delusions and hallucinations. In: Pantelis C, Nelson HE, Barnes TRE, editors. Schizophrenia: a neuropsychological perspective. London: John Wiley & Sons; 1996. p. 205-35.
61. Arolt V, Lencer R, Nolte A, et al. Eye tracking dysfunction is a putative phenotypic susceptibility marker of schizophrenia and maps to a locus on chromosome 6p in families with multiple occurrence of the disease. Am J Med Genet 1996;67:564-79.
62. Lencer R, Malchow CP, Krecker K, et al. Smooth pursuit performance in families with multiple occurrence of schizophrenia and nonpsychotic families. Biol Psychiatry 1999;45:694-703.
63. Jeon YW, Polich J. Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications. Psychophysiology 2003;40:684-701.
64. Bramon E, Rabe-Hesketh S, Sham P, et al. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res 2004;70: 315-29.
65. Bramon E, McDonald C, Croft RJ, et al. Is the P300 wave an endo -phenotype for schizophrenia? A meta-analysis and a family study. Neuroimage 2005;27:960-8.
66. Cadenhead KS, Light GA, Shafer KM, et al. P50 suppression in individuals at risk for schizophrenia: the convergence of clinical, fam ilial, and vulnerability marker risk assessment. Biol Psychiatry 2005;57:1504-9.
67. Aleman A, Hijman R, de Haan EH, et al. Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry 1999;156:1358-66.
68. Toulopoulou T, Rabe-Hesketh S, King H, et al. Episodic memory in schizophrenic patients and their relatives. Schizophr Res 2003;63: 261-71.
69. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 2001;156:234-58.
70. Braff DL, Grillon C, Geyer MA. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 1992;49: 206-15.
71. Broga MI, Neufeld RW. Evaluation of information sequential aspects of schizophrenic performance. I. Framework and current findings. J Nerv Ment Dis 1981;169:558-68.
72. Roussos P, Giakoumaki SG, Rogdaki M, et al. Prepulse inhibition of the startle reflex depends on the catechol O-methyltransferase Val158Met gene polymorphism. Psychol Med 2008;38:1651-8.
73. Dawson ME, Schell AM, Hazlett EA, et al. On the clinical and cognitive meaning of impaired sensorimotor gating in schizophrenia. Psychiatry Res 2000;96:187-97.
74. Braff DL, Swerdlow NR, Geyer MA. Symptom correlates of pre-pulse inhibition deficits in male schizophrenic patients. Am J Psychiatry 1999;156:596-602.
75. Ludewig K, Geyer MA, Vollenweider FX. Deficits in prepulse in -hib ition and habituation in never-medicated, first-episode schizophrenia. Biol Psychiatry 2003;54:121-8.
76. Cadenhead KS, Swerdlow NR, Shafer KM, et al. Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits. Am J Psychiatry 2000;157:1660-8.
77. Ludewig K, Vollenweider FX. Impaired sensorimotor gating in schizophrenia with deficit and with nondeficit syndrome. Swiss Med Wkly 2002;132:159-65.
78. Powell SB, Zhou X, Geyer MA. Prepulse inhibition and genetic mouse models of schizophrenia. Behav Brain Res 2009;204:282-94.
79. Ellenbroek BA. Pre-attentive processing and schizophrenia: animal studies. Psychopharmacology (Berl) 2004;174:65-74.
80. Baddeley A. Working memory: looking back and looking forward. Nat Rev Neurosci 2003;4:829-39.
81. Conklin HM, Curtis CE, Calkins ME, et al. Working memory functioning in schizophrenia patients and their first-degree relatives: cognitive functioning shedding light on etiology. Neuropsychologia 2005;43:930-42.
82. Pirkola T, Tuulio-Henriksson A, Glahn D, et al. Spatial working memory function in twins with schizophrenia and bipolar disorder. Biol Psychiatry 2005;58:930-6.
83. Twamley EW, Palmer BW, Jeste DV, et al. Transient and executive function working memory in schizophrenia. Schizophr Res 2006;87: 185-90.
84. Saperstein AM, Fuller RL, Avila MT, et al. Spatial working memory as a cognitive endophenotype of schizophrenia: assessing risk for pathophysiological dysfunction. Schizophr Bull 2006;32:498-506.
85. Brébion G, David AS, Jones HM, et al. Working memory span and motor and cognitive speed in schizophrenia. Cogn Behav Neurol 2009;22:101-8.
86. O'Connor M, Harris JM, McIntosh AM, et al. Specific cognitive deficits in a group at genetic high risk of schizophrenia. Psychol Med 2009;39:1649-55.
87. Lee J, Park S. Working memory impairments in schizophrenia: a meta-analysis. J Abnorm Psychol 2005;114:599-611.
88. Snitz BE, Macdonald AW III, Carter CS. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull 2006;32:179-94.
89. Neufeld RW. On the centrality and significance of stimulus-encoding deficit in schizophrenia. Schizophr Bull 2007;33:982-93.
90. Mathes B, Wood SJ, Proffitt TM, et al. Early processing deficits in object working memory in first-episode schizophreniform psych -osis and established schizophrenia. Psychol Med 2005;35:1053-62.
91. Neufeld RWJ, Boksman K, Vollick D, et al. Stochastic dynamics of stimulus encoding in schizophrenia: theory, testing, and application. J Math Psychol 2010;54:90-108.
92. Rodriguez-Sanchez JM, Crespo-Facorro B, Gonzalez-Blanch C et al. Cognitive dysfunction in first-episode psychosis: the processing speed hypothesis. Br J Psychiatry Suppl 2007;51:s107-s110.
93. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984;11:47-60.
94. Deacon RM, Rawlins JN. Learning impairments of hippocampal-lesioned mice in a paddling pool. Behav Neurosci 2002;116:472-8.
95. Morris RG, Hagan JJ, Rawlins JN. Allocentric spatial learning by hippocampectomised rats: a further test of the "spatial mapping" and "working memory" theories of hippocampal function. Q J Exp Psychol B 1986;38:365-95.
96. Sandstrom NJ, Kim JH, Wasserman MA. Testosterone modulates performance on a spatial working memory task in male rats. Horm Behav 2006;50:18-26.
97. Koike H, Arguello PA, Kvajo M, et al. Disc1 is mutated in the 129S6/SvEv strain and modulates working memory in mice. Proc Natl Acad Sci U S A 2006;103:3693-7.
98. Castner SA, Goldman-Rakic PS, Williams GV. Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology (Berl) 2004;174:111-25.
99. Ceaser AE, Goldberg TE, Egan MF, et al. Set-shifting ability and schizophrenia: A marker of clinical illness or an intermediate pheno type? Biol Psychiatry 2008;64:782-8.
100. McKirdy J, Sussmann JE, Hall J, et al. Set shifting and reversal learning in patients with bipolar disorder or schizophrenia. Psychol Med 2009;39:1289-93.
101. Morrens M, Hulstijn W, Lewi PJ, et al. Stereotypy in schizophrenia. Schizophr Res 2006;84:397-404.
102. Yogev H, Hadar U, Gutman Y, et al. Perseveration and over-switching in schizophrenia. Schizophr Res 2003;61:315-21.
103. Franke P, Maier W, Hardt J, et al. Cognitive functioning and an hedonia in subjects at risk for schizophrenia. Schizophr Res 1993;10:77-84.
104. Szöke A, Schurhoff F, Mathieu F, et al. Tests of executive functions in first-degree relatives of schizophrenic patients: a meta-analysis. Psychol Med 2005;35:771-82.
105. Geyer MA, Moghaddam B. Animal models relevant to schizophrenia disorders. In: Davis KL, Charney D, Coyle JT, et al., editors. Neuro psychopharmacology: the fifth generation of progress. Philadelphia (PA): Lippincott, Williams and Wilkins; 2002. p. 690-701.
106. Sams-Dodd F. Distinct effects of d-amphetamine and phencycli-dine on the social behaviour of rats. Behav Pharmacol 1995;6:55-65.
107. Sams-Dodd F. Effects of continuous D-amphetamine and phencycli-dine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 1998;19:18-25.
108. Weiner I. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berl) 2003;169:257-97.
109. Vaitl D, Lipp O, Bauer U, et al. Latent inhibition and schizophrenia: Pavlovian conditioning of autonomic responses. Schizophr Res 2002;55:147-58.
110. Gal G, Barnea Y, Biran L, et al. Enhancement of latent inhibition in patients with chronic schizophrenia. Behav Brain Res 2009;197:1-8.
111. Gray NS, Pilowsky LS, Gray JA, et al. Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophr Res 1995;17:95-107.
112. Martins Serra A, Jones SH, Toone B, et al. Impaired associative learning in chronic schizophrenics and their first-degree relatives: a study of latent inhibition and the Kamin blocking effect. Schizophr Res 2001;48:273-89.
113. Gray NS, Snowden RJ. The relevance of irrelevance to schizophrenia. Neurosci Biobehav Rev 2005;29:989-99.
114. Swerdlow NR, Stephany N, Wasserman LC, et al. Intact visual latent inhibition in schizophrenia patients in a within-subject paradigm. Schizophr Res 2005;72:169-83.
115. Bediou B, Franck N, Saoud M, et al. Effects of emotion and identity on facial affect processing in schizophrenia. Psychiatry Res 2005; 133: 149-57.
116. Bellack AS, Morrison RL, Wixted JT et al. An analysis of social competence in schizophrenia. Br J Psychiatry 1990;156:809-18.
117. Halford WK, Hayes RL. Social skills in schizophrenia: assessing the relationship between social skills, psychopathology and community functioning. Soc Psychiatry Psychiatr Epidemiol 1995;30:14-9.
118. Penn DL, Corrigan PW, Bentall RP, et al. Social cognition in schizo -phrenia. Psychol Bull 1997;121:114-32.
119. Craver JC, Pogue-Geile MF. Familial liability to schizophrenia: a sibling study of negative symptoms. Schizophr Bull 1999;25:827-39.
120. Katsanis J, Iacono WG, Beiser M. Anhedonia and perceptual aberration in first-episode psychotic patients and their relatives. J Abnorm Psychol 1990;99:202-6.
121. Miyakawa T, Leiter LM, Gerber DJ, et al. Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci U S A 2003;100:8987-92.
122. Crawley JN. Designing mouse behavioral tasks relevant to autistic-like behaviors. Ment Retard Dev Disabil Res Rev 2004;10:248-58.
123. Sams-Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav Pharmacol 1996;7:3-23.
124. Sams-Dodd F, Lipska BK, Weinberger DR. Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology (Berl) 1997;132: 303-10.
125. Powell CM, Miyakawa T. Schizophrenia-relevant behavioral testing in rodent models: A uniquely human disorder? Biol Psychiatry 2006;59:1198-207.
126. Kas MJ, Gelegen C, Schalkwyk LC, et al. Interspecies comparisons of functional genetic variations and their implications in neuro -psychiatry. Am J Med Genet B Neuropsychiatr Genet 2009;150B:309-17.
127. Ellenbroek BA, Cools AR. Animal models for the negative symptoms of schizophrenia. Behav Pharmacol 2000;11:223-33.
128. McDannald M, Schoenbaum G. Toward a model of impaired reality testing in rats. Schizophr Bull 2009;35:664-7.
129. Marcotte ER, Pearson DM, Srivastava LK. Animal models of schizo -phrenia: a critical review. J Psychiatry Neurosci 2001;26:395-410.
130. Shultz SR, Macfabe DF, Ossenkopp KP, et al. Intracerebroventricu-lar injection of propionic acid, an enteric bacterial metabolic end-product, impairs social behavior in the rat: implications for an animal model of autism. Neuropharmacology 2008;54:901-11.
131. Rogers DC, Jones DN, Nelson PR, et al. Use of SHIRPA and discriminant analysis to characterise marked differences in the behavioural phenotype of six inbred mouse strains. Behav Brain Res 1999; 105:207-17.
132. Ellenbroek BA. Animal models in the genomic era: possibilities and limitations with special emphasis on schizophrenia. Behav Pharmacol 2003;14:409-17.
133. Ellison GD, Eison MS. Continuous amphetamine intoxication: an animal model of the acute psychotic episode. Psychol Med 1983;13: 751-61.
134. Mandillo S, Rinaldi A, Oliverio A, et al. Repeated administration of phencyclidine, amphetamine and MK-801 selectively impairs spatial learning in mice: a possible model of psychotomimetic drug-induced cognitive deficits. Behav Pharmacol 2003;14:533-44.
135. Mansbach RS, Geyer MA, Braff DL. Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology (Berl) 1988;94:507-14.
136. Steinpreis RE, Sokolowski JD, Papanikolaou A, et al. The effects of haloperidol and clozapine on PCP- and amphetamine-induced suppression of social behavior in the rat. Pharmacol Biochem Behav 1994;47:579-85.
137. Ellenbroek BA, Budde S, Cools AR. Prepulse inhibition and latent inhibition: the role of dopamine in the medial prefrontal cortex. Neuroscience 1996;75:535-42.
138. Andersen JD, Pouzet B. Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of D-serine. Neuropsychopharmacology 2004;29:1080-90.
139. Rasmussen BA, O'Neil J, Manaye KF, et al. Long-term effects of developmental PCP administration on sensorimotor gating in male and female rats. Psychopharmacology (Berl) 2007;190:43-9.
140. Sams-Dodd F. Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev Neurosci 1999;10:59-90.
141. Brigman JL, Ihne, J, Saksida, LM et al. Effects of subchronic phen-cyclidine (PCP) treatment on social behaviors, and operant discrimination and reversal learning in C57BL/6J mice. Front Behav Neurosci 2009;3:2.
142. Liu J, Suzuki T, Seki T, et al. Effects of repeated phencyclidine ad mi n istration on adult hippocampal neurogenesis in the rat. Synapse 2006;60:56-68.
143. Sams-Dodd F. Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav Pharmacol 1997;8:196-215.
144. Sams-Dodd F. Effects of diazepam, citalopram, methadone and naloxone on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Neurosci Biobehav Rev 1998;23:287-93.
145. Becker A, Peters B, Schroeder H, et al. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:687-700.
146. Becker A, Grecksch G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1267-77.
147. Baier PC, Blume A, Koch J, et al. Early postnatal depletion of NMDA receptor development affects behaviour and NMDA receptor expression until later adulthood in rats - a possible model for schizophrenia. Behav Brain Res 2009;205:96-101.
148. Japha K, Koch M. Picrotoxin in the medial prefrontal cortex impairs sensorimotor gating in rats: reversal by haloperidol. Psycho pharmacology (Berl) 1999;144:347-54.
149. Berretta S, Munno DW, Benes FM. Amygdalar activation alters the hippocampal GABA system: "partial" modelling for postmortem changes in schizophrenia. J Comp Neurol 2001;431:129-38.
150. Berretta S, Lange N, Bhattacharyya S, et al. Long-term effects of amygdala GABA receptor blockade on specific subpopulations of hippocampal interneurons. Hippocampus 2004;14:876-94.
151. Gisabella B, Cunningham MG, Bolshakov VY, et al. Amygdala-dependent regulation of electrical properties of hippocampal inter -neurons in a model of schizophrenia. Biol Psychiatry 2009;65: 464-72.
152. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull 2009;35:549-62.
153. Paz RD, Tardito S, Atzori M, et al. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol 2008;18:773-86.
154. Gainetdinov RR, Mohn AR, Caron MG. Genetic animal models: focus on schizophrenia. Trends Neurosci 2001;24:527-33.
155. Ralph RJ, Paulus MP, Fumagalli F, et al. Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. J Neurosci 2001;21:305-13.
156. Spielewoy C, Roubert C, Hamon M, et al. Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice. Behav Pharmacol 2000;11:279-90.
157. Fradley RL, O'Meara GF, Newman RJ, et al. STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav Brain Res 2005;163:257-64.
158. Halene TB, Ehrlichman RS, Liang Y, et al. Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia. Genes Brain Behav 2009;8:661-75.
159. Mohn AR, Gainetdinov RR, Caron MG, et al. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999;98:427-36.
160. Chen J, Lipska BK, Weinberger DR. Genetic mouse models of schizophrenia: from hypothesis-based to susceptibility gene-based models. Biol Psychiatry 2006;59:1180-8.
161. Brown AS, Begg MD, Gravenstein S, et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 2004;61:774-80.
162. Kendell RE, Kemp IW. Maternal influenza in the etiology of schizo -phrenia. Arch Gen Psychiatry 1989;46:878-82.
163. Brown AS. Prenatal infection as a risk factor for schizophrenia. Schizophr Bull 2006;32:200-2.
164. Fatemi SH, Reutiman TJ, Folsom TD, et al. Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: implications for genesis of neurodevelopmental disorders. Schizophr Res 2008;99:56-70.
165. Fatemi SH, Pearce DA, Brooks AI, et al. Prenatal viral infection in mouse causes differential expression of genes in brains of mouse progeny: a potential animal model for schizophrenia and autism. Synapse 2005;57:91-9.
166. Shi L, Fatemi SH, Sidwell RW, et al. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci 2003;23:297-302.
167. Boksa P. Maternal infection during pregnancy and schizophrenia. J Psychiatry Neurosci 2008;33:183-5.
168. Boksa P. Animal models of obstetric complications in relation to schizophrenia. Brain Res Brain Res Rev 2004;45:1-17.
169. Engel JA, Zhang J, Bergstrom T, et al. Neonatal herpes simplex virus type 1 brain infection affects the development of sensorimotor gating in rats. Brain Res 2000;863:233-40.
170. Pletnikov MV, Rubin SA, Vogel MW, et al. Effects of genetic background on neonatal Borna disease virus infection-induced neuro -developmental damage. II. Neurochemical alterations and responses to pharmacological treatments. Brain Res 2002;944:108-23.
171. Ashdown H, Dumont Y, Ng M, et al. The role of cytokines in mediating effects of prenatal infection on the fetus: implications for schizophrenia. Mol Psychiatry 2006;11:47-55.
172. Shi L, Tu N, Patterson PH. Maternal influenza infection is likely to alter fetal brain development indirectly: the virus is not detected in the fetus. Int J Dev Neurosci 2005;23:299-305.
173. Meyer U, Feldon J, Schedlowski M, et al. Immunological stress at the maternal-foetal interface: a link between neurodevelopment and adult psychopathology. Brain Behav Immun 2006;20:378-88.
174. Nawa H, Takei N. Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. Neurosci Res 2006;56:2-13.
175. Patterson PH. Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res 2009;204: 313-21.
176. Dalman C, Allebeck P, Cullberg J, et al. Obstetric complications and the risk of schizophrenia: a longitudinal study of a national birth cohort. Arch Gen Psychiatry 1999;56:234-40.
177. Geddes JR, Lawrie SM. Obstetric complications and schizophrenia: a meta-analysis. Br J Psychiatry 1995;167:786-93.
178. Avila MT, Sherr J, Valentine LE, et al. Neurodevelopmental interactions conferring risk for schizophrenia: a study of dermato-glyphic markers in patients and relatives. Schizophr Bull 2003;29: 595-605.
179. Rapoport JL, Addington AM, Frangou S, et al. The neurodevelop-mental model of schizophrenia: update 2005. Mol Psychiatry 2005; 10:434-49.
180. Nicodemus KK, Marenco S, Batten AJ, et al. Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk. Mol Psychiatry 2008;13:873-7.
181. Nicholson IR, Neufeld RW. A dynamic vulnerability perspective on stress and schizophrenia. Am J Orthopsychiatry 1992;62:117-30.
182. Boksa P, El-Khodor BF. Birth insult interacts with stress at adulthood to alter dopaminergic function in animal models: possible implications for schizophrenia and other disorders. Neurosci Biobehav Rev 2003;27:91-101.
183. Laviola G, Adriani W, Rea M, et al. Social withdrawal, neophobia, and stereotyped behavior in developing rats exposed to neonatal asphyxia. Psychopharmacology (Berl) 2004;175:196-205.
184. Tan YL, Zhou DF, Cao LY, et al. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with anti psychotics. Neurosci Lett 2005;382:27-32.
185. Toyooka K, Asama K, Watanabe Y, et al. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 2002;110:249-57.
186. Kohlhauser C, Mosgoeller W, Hoeger H, et al. Cholinergic, monoaminergic and glutamatergic changes following perinatal asphyxia in the rat. Cell Mol Life Sci 1999;55:1491-501.
187. Berger MA, Barros VG, Sarchi MI, et al. Long-term effects of prenatal stress on dopamine and glutamate receptors in adult rat brain. Neurochem Res 2002;27:1525-33.
188. Kofman O. The role of prenatal stress in the etiology of developmental behavioural disorders. Neurosci Biobehav Rev 2002;26:457-70.
189. Ellenbroek BA, Derks N, Park HJ. Early maternal deprivation retards neurodevelopment in Wistar rats. Stress 2005;8:247-57.
190. Garner B, Wood SJ, Pantelis C, et al. Early maternal deprivation reduces prepulse inhibition and impairs spatial learning ability in adulthood: no further effect of post-pubertal chronic corticsterone treatment. Behav Brain Res 2007;176:323-32.
191. Lipska BK. Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J Psychiatry Neurosci 2004;29:282-6.
192. Flores G, Silva-Gomez AB, Ibanez O, et al. Comparative behavioral changes in postpubertal rats after neonatal excitotoxic lesions of the ventral hippocampus and the prefrontal cortex. Synapse 2005; 56:147-53.
193. Becker A, Grecksch G, Bernstein HG, et al. Social behaviour in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis. Psychopharmacology (Berl) 1999;144:333-8.
194. Grecksch G, Bernstein HG, Becker A, et al. Disruption of latent inhibition in rats with postnatal hippocampal lesions. Neuropsychopharmacology 1999;20:525-32.
195. Lipska BK, Swerdlow NR, Geyer MA, et al. Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in pre-pulse inhibition of startle and its disruption by apomorphine. Psychopharmacology (Berl) 1995;122:35-43.
196. Lipska BK, Aultman JM, Verma A, et al. Neonatal damage of the ventral hippocampus impairs working memory in the rat. Neuro psychopharmacology 2002;27:47-54.
197. Schroeder H, Grecksch G, Becker A, et al. Alterations of the dopaminergic and glutamatergic neurotransmission in adult rats with postnatal ibotenic acid hippocampal lesion. Psychopharmacology (Berl) 1999;145:61-6.
198. Tseng KY, Lewis BL, Hashimoto T, et al. A neonatal ventral hip-pocampal lesion causes functional deficits in adult prefrontal cortic al interneurons. J Neurosci 2008;28:12691-9.
199. François J, Ferrandon A, Koning E, et al. Selective reorganization of GABAergic transmission in neonatal ventral hippocampal-lesioned rats. Int J Neuropsychopharmacol 2009;12:1097-110.
200. Tseng KY, Chambers RA, Lipska BK. The neonatal ventral hip-pocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav Brain Res 2009;204:295-305.
201. Schneider M, Koch M. Behavioral and morphological alterations following neonatal excitotoxic lesions of the medial prefrontal cortex in rats. Exp Neurol 2005;195:185-98.
202. Schneider M, Koch M. Deficient social and play behavior in juven -ile and adult rats after neonatal cortical lesion: effects of chronic pubertal cannabinoid treatment. Neuropsychopharmacology 2005;30: 944-57.
203. Schneider M, Koch M. The effect of chronic peripubertal cannabin -oid treatment on deficient object recognition memory in rats after neonatal mPFC lesion. Eur Neuropsychopharmacol 2007;17:180-6.
204. Bennay M, Gernert M, Schwabe K, et al. Neonatal medial pre-frontal cortex lesion enhances the sensitivity of the mesoaccumbal dopamine system. Eur J Neurosci 2004;19:3277-90.
205. Talamini LM, Koch T, Ter Horst GJ, et al. Methylazoxymethanol acetate-induced abnormalities in the entorhinal cortex of the rat; parallels with morphological findings in schizophrenia. Brain Res 1998;789:293-306.
206. Fiore M, Korf J, Angelucci F, et al. Prenatal exposure to methyla-zoxymethanol acetate in the rat alters neurotrophin levels and behavior: considerations for neurodevelopmental diseases. Physiol Behav 2000;71:57-67.
207. Talamini LM, Koch T, Luiten PG, et al. Interruptions of early cortic al development affect limbic association areas and social behaviour in rats; possible relevance for neurodevelopmental disorders. Brain Res 1999;847:105-20.
208. Flagstad P, Glenthoj BY, Didriksen M. Cognitive deficits caused by late gestational disruption of neurogenesis in rats: a preclinical model of schizophrenia. Neuropsychopharmacology 2005;30:250-60.
209. Flagstad P, Mork A, Glenthoj BY, et al. Disruption of neurogenesis on gestational day 17 in the rat causes behavioral changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopamine release in nucleus accumbens. Neuro psychopharmacology 2004;29:2052-64.
210. Moore H, Jentsch JD, Ghajarnia M, et al. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry 2006;60:253-64.
211. Futamura T, Kakita A, Tohmi M, et al. Neonatal perturbation of neurotrophic signaling results in abnormal sensorimotor gating and social interaction in adults: implication for epidermal growth factor in cognitive development. Mol Psychiatry 2003;8:19-29.
212. Sotoyama H, Namba H, Takei N, et al. Neonatal exposure to epidermal growth factor induces dopamine D2-like receptor supersensitivity in adult sensorimotor gating. Psychopharmacology (Berl) 2007;191: 783-92.
213. Rajakumar N, Leung LS, Ma J, et al. Altered neurotrophin receptor function in the developing prefrontal cortex leads to adult-onset dopaminergic hyperresponsivity and impaired prepulse inhibition of acoustic startle. Biol Psychiatry 2004;55:797-803.
214. Rajakumar N, Rajakumar B. A mild disruption of subplate function in the developing prefrontal cortex is sufficient to cause multiple neuropathological features of schizophrenia. Biennial Meeting of the International Society for Schizophrenia Research; April 2005; Savannah, Ga.
215. Lazar NL, Rajakumar N, Cain DP. Injections of NGF into neonatal frontal cortex decrease social interaction as adults: a rat model of schizophrenia. Schizophr Bull 2008;34:127-36.
216. Lavin A, Moore HM, Grace AA. Prenatal disruption of neocortical development alters prefrontal cortical neuron responses to dopa -mine in adult rats. Neuropsychopharmacology 2005;30:1426-35.
217. Sham P, McGiffin P. Linkage and association. In: McGuffin P, Owen MJ, Gottesman II, editors. Psychiatric genetics and genomics. New York (NY): Oxford University Press; 2001. p. 55-76.
218. Gottesman II, Moldin SO. Genotyoes, genes, genesis, and patho-genesis in schizophrenia. In: Lenzenweger MF, Dworkin RH, editors. Origins and development of schizophrenia: advances in experiment -al psychopathology. Washington (DC): American Psychological Association; 1998. p. 5-26.
219. Badner JA, Gershon ES. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 2002; 7:405-11.
220. Lewis CM, Levinson DF, Wise LH, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet 2003;73:34-48.
221. Holmans PA, Riley B, Pulver AE, et al. Genomewide linkage scan of schizophrenia in a large multicenter pedigree sample using single nucleotide polymorphisms. Mol Psychiatry 2009;14:786-95.
222. Sobin C, Kiley-Brabeck K, Karayiorgou M. Lower prepulse inhib -ition in children with the 22q11 deletion syndrome. Am J Psychiatry 2005;162:1090-9.
223. Sobin C, Kiley-Brabeck K, Daniels S, et al. Neuropsychological characteristics of children with the 22q11 deletion syndrome: a descriptive analysis. Child Neuropsychol 2005;11:39-53.
224. Jolin EM, Weller RA, Weller EB. Psychosis in children with velo -cardio facial syndrome (22q11.2 deletion syndrome). Curr Psychiatry Rep 2009;11:99-105.
225. Karayiorgou M, Gogos JA. The molecular genetics of the 22q11-associated schizophrenia. Brain Res Mol Brain Res 2004;132:95-104.
226. Joober R, Boksa P, Benkelfat C, et al. Genetics of schizophrenia: from animal models to clinical studies. J Psychiatry Neurosci 2002; 27:336-47.
227. Bender HU, Almashanu S, Steel G, et al. Functional consequences of PRODH missense mutations. Am J Hum Genet 2005;76:409-20.
228. Kempf L, Nicodemus KK, Kolachana B, et al. Functional poly -morphisms in PRODH are associated with risk and protection for schizophrenia and fronto-striatal structure and function. PLoS Genet 2008;4:e1000252.
229. Zinkstok J, Schmitz, N, van Amelsvoort T, et al. Genetic variation in COMT and PRODH is associated with brain anatomy in patients with schizophrenia. Genes Brain Behav 2008;7:61-9.
230. Liu H, Heath SC, Sobin C, et al. Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. Proc Natl Acad Sci U S A 2002; 99:3717-22.
231. Jacquet H, Raux G, Thibaut F, et al. PRODH mutations and hyper-prolinemia in a subset of schizophrenic patients. Hum Mol Genet 2002;11:2243-9.
232. Li T, Ma X, Sham PC, et al. Evidence for association between novel polymorphisms in the PRODH gene and schizophrenia in a Chinese population. Am J Med Genet B Neuropsychiatr Genet 2004; 129B:13-5.
233. Jacquet H, Demily C, Houy E, et al. Hyperprolinemia is a risk factor for schizoaffective disorder. Mol Psychiatry 2005;10:479-85.
234. Ma X, Sun J, Yao J, et al. A quantitative association study between schizotypal traits and COMT, PRODH and BDNF genes in a healthy Chinese population. Psychiatry Res 2007;153:7-15.
235. Ohtsuki T, Tanaka S, Ishiguro H, et al. Failure to find association between PRODH deletion and schizophrenia. Schizophr Res 2004; 67:111-3.
236. Williams HJ, Williams N, Spurlock G, et al. Association between PRODH and schizophrenia is not confirmed. Mol Psychiatry 2003;8: 644-5.
237. Roussos P, Giakoumaki SG, Bitsios P. A risk PRODH haplotype affects sensorimotor gating, memory, schizotypy, and anxiety in healthy male subjects. Biol Psychiatry 2009;65:1063-70.
238. Stark KL, Burt RA, Gogos JA, et al. Analysis of prepulse inhibition in mouse lines overexpressing 22q11.2 orthologues. Int J Neuropsycho pharmacol 2009 Jun. 11: 1-7. [Epub ahead of print]
239. Gogos JA, Santha M, Takacs Z, et al. The gene encoding proline dehydrogenase modulates sensorimotor gating in mice. Nat Genet 1999;21:434-9.
240. Paterlini M, Zakharenko SS, Lai WS, et al. Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nat Neurosci 2005; 8: 1586-94.
241. Ross CA, Margolis RL, Reading SA, et al. Neurobiology of schizophrenia. Neuron 2006;52:139-53.
242. Brisch R, Bernstein, HG, Krell, D et al. Dopamine-glutamate abnormalities in the frontal cortex associated with the catechol-O-methyltransferase (COMT) in schizophrenia. Brain Res 2009; 1269:166-75.
243. Rutherford K, Daggett V. A hotspot of inactivation: the A22S and V108M polymorphisms individually destabilize the active site structure of catechol O-methyltransferase. Biochemistry 2009;48: 6450-60.
244. Honea R, Verchinski BA, Pezawas L, et al. Impact of interacting functional variants in COMT on regional gray matter volume in human brain. Neuroimage 2009;45:44-51.
245. Fan JB, Zhang CS, Gu NF, et al. Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis. Biol Psychiatry 2005;57:139-44.
246. Gupta M, Bhatnagar P, Grover S, et al. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 2009;10:385-97.
247. Handoko HY, Nyholt DR, Hayward NK, et al. Separate and interacting effects within the catechol-O-methyltransferase (COMT) are associated with schizophrenia. Mol Psychiatry 2005;10:589-97.
248. Okochi T, Ikeda M, Kishi T, et al. Meta-analysis of association between genetic variants in COMT and schizophrenia: an update. Schizophr Res 2009;110:140-8.
249. Williams HJ, Glaser B, Williams NM, et al. No association between schizophrenia and polymorphisms in COMT in two large samples. Am J Psychiatry 2005;162:1736-8.
250. Quednow BB, Wagner M, Mossner R, et al. Sensorimotor gating of schizophrenia patients depends on catechol O-methyltransferase Val158Met polymorphism. Schizophr Bull 2010;36:341-6.
251. Barnett JH, Jones PB, Robbins TW, et al. Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls. Mol Psychiatry 2007;12:502-9.
252. Liao SY, Lin SH, Liu CM, et al. Genetic variants in COMT and neuro cognitive impairment in families of patients with schizophrenia. Genes Brain Behav 2009;8:228-37.
253. Docherty AR, Sponheim SR. Anhedonia as a phenotype for the Val158Met COMT polymorphism in relatives of patients with schizophrenia. J Abnorm Psychol 2008;117:788-98.
254. Gogos JA, Morgan M, Luine V, et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci U S A 1998;95:9991-6.
255. Huotari M, Santha M, Lucas LR, et al. Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice. J Pharmacol Exp Ther 2002; 303:1309-16.
256. Schmitt A, Parlapani, E, Gruber, O et al. Impact of neuregulin-1 on the pathophysiology of schizophrenia in human post-mortem studies. Eur Arch Psychiatry Clin Neurosci 2008;258 Suppl 5:35-9.
257. Hall J, Whalley HC, Job DE, et al. A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. Nat Neurosci 2006;9:1477-8.
258. Mata I, Perez-Iglesias R, Roiz-Santianez R, et al. A neuregulin 1 variant is associated with increased lateral ventricle volume in patients with first-episode schizophrenia. Biol Psychiatry 2009;65:535-40.
259. Scolnick EM, Petryshen T, Sklar P. Schizophrenia: Do the genetics and neurobiology of neuregulin provide a pathogenesis model? Harv Rev Psychiatry 2006;14:64-77.
260. Bakker SC, Hoogendoorn ML, Selten JP, et al. Neuregulin 1: genetic support for schizophrenia subtypes. Mol Psychiatry 2004;9:1061-3.
261. Prata DP, Breen G, Osborne S, et al. An association study of the neuregulin 1 gene, bipolar affective disorder and psychosis. Psychiatr Genet 2009;19:113-6.
262. Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002;71:877-92.
263. Jönsson EG, Saetre P, Vares M, et al. DTNBP1, NRG1, DAOA, DAO and GRM3 polymorphisms and schizophrenia: an association study. Neuropsychobiology 2009;59:142-50.
264. Vilella E, Costas J, Sanjuan J, et al. Association of schizophrenia with DTNBP1 but not with DAO, DAOA, NRG1 and RGS4 nor their genetic interaction. J Psychiatr Res 2008;42:278-88.
265. Li D, Collier DA, He L. Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. Hum Mol Genet 2006;15:1995-2002.
266. Gong YG, Wu CN, Xing QH, et al. A two-method meta-analysis of Neuregulin 1(NRG1) association and heterogeneity in schizophrenia. Schizophr Res 2009;111:109-14.
267. Rimer M, Barrett DW, Maldonado MA, et al. Neuregulin-1 immunoglobulin-like domain mutant mice: clozapine sensitivity and impaired latent inhibition. Neuroreport 2005;16:271-5.
268. van den Buuse M, Wischhof L, Lee RX, et al. Neuregulin 1 hypo-morphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. Int J Neuropsychopharmacol 2009;12:1383-93.
269. Millar JK, Wilson-Annan JC, Anderson S, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet 2000;9:1415-23.
270. Meyer KD, Morris JA. Disc1 regulates granule cell migration in the developing hippocampus. Hum Mol Genet 2009;18:3286-97.
271. Millar JK, James R, Brandon NJ, et al. Drosoph Inf ServC1 and Drosoph Inf ServC2: discovering and dissecting molecular mech -an isms underlying psychiatric illness. Ann Med 2004;36:367-78.
272. Prata DP, Mechelli A, Fu CH, et al. Effect of disrupted-in-schizophrenia-1 on pre-frontal cortical function. Mol Psychiatry 2008;13: 915-7, 909.
273. Szeszko PR, Hodgkinson CA, Robinson DG, et al. Drosoph Inf ServC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia. Biol Psychol 2008;79:103-10.
274. Takahashi T, Suzuki M, Tsunoda M, et al. The disrupted-in-schizophrenia-1 Ser704Cys polymorphism and brain morphology in schizophrenia. Psychiatry Res 2009;172:128-35.
275. Blackwood DH, Fordyce A, Walker MT, et al. Schizophrenia and affective disorders - cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet 2001;69:428-33.
276. Ekelund J, Hovatta I, Parker A, et al. Chromosome 1 loci in Finnish schizophrenia families. Hum Mol Genet 2001;10:1611-7.
277. Sachs NA, Sawa A, Holmes SE, et al. A frameshift mutation in disrupted in schizophrenia 1 in an American family with schizophrenia and schizoaffective disorder. Mol Psychiatry 2005;10:758-64.
278. Saetre P, Agartz I, De FA, et al. Association between a disrupted-in-schizophrenia 1 (Drosoph Inf ServC1) single nucleotide polymorphism and schizophrenia in a combined Scandinavian case-control sample. Schizophr Res 2008;106:237-41.
279. Schumacher J, Laje G, Abou JR, et al. The Drosoph Inf ServC locus and schizophrenia: evidence from an association study in a central European sample and from a meta-analysis across different European populations. Hum Mol Genet 2009;18:2719-27.
280. Tomppo L, Hennah W, Miettunen J, et al. Association of variants in Drosoph Inf ServC1 with psychosis-related traits in a large popu lation cohort. Arch Gen Psychiatry 2009;66:134-41.
281. Clapcote SJ, Lipina TV, Millar JK, et al. Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 2007;54:387-402.
282. Kvajo M, McKellar H, Arguello PA, et al. A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc Natl Acad Sci U S A 2008; 105: 7076-81.
283. Pletnikov MV, Ayhan, Y, Nikolskaia, O et al. Inducible expression of mutant human Drosoph Inf ServC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol Psychiatry 2008;13:173-86, 115.
284. Shen S, Lang B, Nakamoto C, et al. Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated Disc1. J Neurosci 2008;28:10893-904.
285. Yue W, Kang G, Zhang Y, et al. Association of DAOA polymorph -isms with schizophrenia and clinical symptoms or therapeutic effects. Neurosci Lett 2007;416:96-100.
286. Chumakov I, Blumenfeld M, Guerassimenko O, et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A 2002;99:13675-80.
287. Shinkai T, DeLuac V, Hwang R, et al. Association analyses of the DAOA/G30 and D-amino-acid oxidase genes in schizophrenia: further evidence for a role in schizophrenia. Neuromolecular Med 2007; 9:169-77.
288. Shin HD, Park BL, Kim EM, et al. Association analysis of G72/G30 polymorphisms with schizophrenia in the Korean population. Schizophr Res 2007;96:119-24.
289. Shi J, Badner JA, Gershon ES, et al. Further evidence for an association of G72/G30 with schizophrenia in Chinese. Schizophr Res 2009;107:324-6.
290. Liu YL, Fann CS, Liu CM, et al. No association of G72 and D-amino acid oxidase genes with schizophrenia. Schizophr Res 2006;87:15-20.
291. Li D, He L. G72/G30 genes and schizophrenia: a systematic meta-analysis of association studies. Genetics 2007;175:917-22.
292. Jansen A, Krach S, Krug A, et al. A putative high risk diplotype of the G72 gene is in healthy individuals associated with better performance in working memory functions and altered brain activity in the medial temporal lobe. Neuroimage 2009;45:1002-8.
293. Otte DM, Bilkei-Gorzo A, Filiou MD, et al. Behavioral changes in G72/G30 transgenic mice. Eur Neuropsychopharmacol 2009;19:339-48.
294. Owen MJ, Williams NM, O'Donovan MC. Dysbindin-1 and schizophrenia: from genetics to neuropathology. J Clin Invest 2004;113: 1255-7.
295. Weickert CS, Straub RE, McClintock BW, et al. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch Gen Psychiatry 2004;61:544-55.
296. Duan J, Martinez M, Sanders AR, et al. DTNBP1 (Dystrobrevin binding protein 1) and schizophrenia: association evidence in the 3′ end of the gene. Hum Hered 2007;64:97-106.
297. Pae CU, Mandelli L, De RD, et al. Dysbindin gene (DTNBP1) and schizophrenia in Korean population. Eur Arch Psychiatry Clin Neurosci 2009;259:137-42.
298. Tosato S, Ruggeri M, Bonetto C, et al. Association study of dys-bindin gene with clinical and outcome measures in a representative cohort of Italian schizophrenic patients. Am J Med Genet B Neuropsychiatr Genet 2007;144B:647-59.
299. Datta SR, McQuillin A, Puri V, et al. Failure to confirm allelic and haplotypic association between markers at the chromosome 6p22.3 dystrobrevin-binding protein 1 (DTNBP1) locus and schizophrenia. Behav Brain Funct 2007;3:50.
300. Holliday EG, Handoko HY, James MR, et al. Association study of the dystrobrevin-binding gene with schizophrenia in Australian and Indian samples. Twin Res Hum Genet 2006;9:531-9.
301. Peters K, Wiltshire S, Henders AK, et al. Comprehensive analysis of tagging sequence variants in DTNBP1 shows no association with schizophrenia or with its composite neurocognitive endopheno types. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 1159-66.
302. Li D, He L. Association study between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia: a meta-analysis. Schizophr Res 2007;96:112-8.
303. Donohoe G, Morris DW, Clarke S, et al. Variance in neurocognitive performance is associated with dysbindin-1 in schizophrenia: a preliminary study. Neuropsychologia 2007;45:454-8.
304. Hashimoto R, Noguchi H, Hori H, et al. A genetic variation in the dysbindin gene (DTNBP1) is associated with memory performance in healthy controls. World J Biol Psychiatry 2010;11:431-8.
305. Takao K, Toyama K, Nakanishi K, et al. Impaired long-term memory retention and working memory in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Mol Brain 2008;1:11.
306. Cox MM, Tucker AM, Tang J, et al. Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/6J genetic background. Genes Brain Behav 2009;8:390-7.
307. Feng YQ, Zhou ZY, He X, et al. Dysbindin deficiency in sandy mice causes reduction of snapin and displays behaviors related to schizophrenia. Schizophr Res 2008;106:218-28.
308. Hattori S, Murotani T, Matsuzaki S, et al. Behavioral abnormalities and dopamine reductions in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Biochem Biophys Res Commun 2008;373:298-302.
309. Sinibaldi L, De LA, Bellacchio E, et al. Mutations of the Nogo-66 receptor (RTN4R) gene in schizophrenia. Hum Mutat 2004;24:534-5.
310. Novak G, Kim D, Seeman P, et al. Schizophrenia and Nogo: elevated mRNA in cortex, and high prevalence of a homozygous CAA insert. Brain Res Mol Brain Res 2002;107:183-9.
311. Novak G, Tallerico T, Nogo A. B and C expression in schizophrenia, depression and bipolar frontal cortex, and correlation of Nogo expression with CAA/TATC polymorphism in 3′-UTR. Brain Res 2006;1120:161-71.
312. Chen W, Gu N, Duan S, et al. No association between the genetic polymorphisms within RTN4 and schizophrenia in the Chinese population. Neurosci Lett 2004;365:23-7.
313. Gregório SP, Mury FB, Ojopi EB, et al. Nogo CAA 3′UTR insertion polymorphism is not associated with schizophrenia nor with bi -polar disorder. Schizophr Res 2005;75:5-9.
314. Budel S, Padukkavidana T, Liu BP, et al. Genetic variants of Nogo-66 receptor with possible association to schizophrenia block myelin inhibition of axon growth. J Neurosci 2008;28:13161-72.
315. Hsu R, Woodroffe A, Lai WS, et al. Nogo Receptor 1 (RTN4R) as a candidate gene for schizophrenia: analysis using human and mouse genetic approaches. PLoS ONE 2007;2:e1234.
316. Meng J, Shi Y, Zhao X, et al. No association between the genetic polymorphisms in the RTN4R gene and schizophrenia in the Chinese population. J Neural Transm 2007;114:249-54.
317. Buckholtz JW, Meyer-Lindenberg A, Honea RA, et al. Allelic variation in RGS4 impacts functional and structural connectivity in the human brain. J Neurosci 2007;27:1584-93.
318. Chowdari KV, Mirnics K, Semwal P, et al. Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum Mol Genet 2002;11:1373-80.
319. So HC, Chen RY, Chen EY, et al. An association study of RGS4 polymorphisms with clinical phenotypes of schizophrenia in a Chinese population. Am J Med Genet B Neuropsychiatr Genet 2008; 147B:77-85.
320. Talkowski ME, Seltman H, Bassett AS, et al. Evaluation of a susceptibility gene for schizophrenia: genotype based meta-analysis of RGS4 polymorphisms from thirteen independent samples. Biol Psychiatry 2006;60:152-62.
321. Guo S, Tang W, Shi Y, et al. RGS4 polymorphisms and risk of schizophrenia: an association study in Han Chinese plus meta-analysis. Neurosci Lett 2006;406:122-7.
322. Li D, He L. Association study of the G-protein signaling 4 (RGS4) and proline dehydrogenase (PRODH) genes with schizophrenia: a meta-analysis. Eur J Hum Genet 2006;14:1130-5.
323. Grillet N, Pattyn A, Contet C, et al. Generation and characterization of Rgs4 mutant mice. Mol Cell Biol 2005;25:4221-8.
324. Mukai J, Liu H, Burt RA, et al. Evidence that the gene encoding ZDHHC8 contributes to the risk of schizophrenia. Nat Genet 2004; 36:725-31.
325. Liu H, Abecasis GR, Heath SC, et al. Genetic variation in the 22q11 locus and susceptibility to schizophrenia. Proc Natl Acad Sci U S A 2002;99:16859-64.
326. Chen WY, Shi YY, Zheng YL, et al. Case-control study and transmission disequilibrium test provide consistent evidence for association between schizophrenia and genetic variation in the 22q11 gene ZDHHC8. Hum Mol Genet 2004;13:2991-5.
327. Faul T, Gawlik M, Bauer M, et al. ZDHHC8 as a candidate gene for schizophrenia: analysis of a putative functional intronic marker in case-control and family-based association studies. BMC Psychiatry 2005;5:35.
328. Otani K, Ujike H, Tanaka Y, et al. The ZDHHC8 gene did not associate with bipolar disorder or schizophrenia. Neurosci Lett 2005; 390: 166-70.
329. Mukai J, Dhilla A, Drew LJ, et al. Palmitoylation-dependent neuro -developmental deficits in a mouse model of 22q11 microdeletion. Nat Neurosci 2008;11:1302-10.
330. Nicodemus KK, Kolachana BS, Vakkalanka R, et al. Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and Drosoph Inf ServC1: influence on risk of schizophrenia. Hum Genet 2007; 120: 889-906.
331. Moncrieff J, Cohen D. How do psychiatric drugs work? BMJ 2009; 338:b1963.
332. Lesch KP. Gene transfer to the brain: Emerging therapeutic strategy in psychiatry? Biol Psychiatry 1999;45:247-53.
333. Clapcote SJ, Roder JC. Deletion polymorphism of Disc1 is common to all 129 mouse substrains: implications for gene-targeting studies of brain function. Genetics 2006;173:2407-10.
334. Anagnostopoulos AV, Mobraaten LE, Sharp JJ, et al. Transgenic and knockout databases: behavioral profiles of mouse mutants. Physiol Behav 2001;73:675-89.
335. Clapcote SJ, Lazar NL, Bechard AR, et al. NIH Swiss and Black Swiss mice have retinal degeneration and performance deficits in cognitive tests. Comp Med 2005;55:310-6.
336. Clapcote SJ, Lazar NL, Bechard AR, et al. Effects of the rd1 mutation and host strain on hippocampal learning in mice. Behav Genet 2005;35:591-601.